Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia
Science Advances · 17.10.2025 · 11 (42)
DOI: 10.1126/sciadv.adx8662 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 17.10.2025. Verfasst von Sofia La Vecchia und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, GTP Phosphohydrolases, Drug Resistance, Neoplasm, Mitochondria. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIEHS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is the most prevalent and deadliest adult leukemia. Its frontline treatment uses the BH3 mimetic venetoclax to trigger mitochondria-dependent apoptosis. However, drug resistance nearly always develops, calling for therapies to circumvent it. Advanced microscopy and genome-wide CRISPRi screen analyses pinpointed mitochondrial adaptations primarily mediated by the master regulator of cristae shape optic atrophy 1 (OPA1) as critical for BH3 mimetics resistance. Resistant AML cells up-regulate OPA1 to modify their mitochondrial structure and evade apoptosis. MYLS22 and Opitor-0, two specific and nontoxic OPA1 inhibitors, promote apoptotic cristae remodeling and cytochrome c release, synergizing with venetoclax in AML cells and xenografts derived from AML patients ex vivo and in vivo. Mechanistically, OPA1 loss renders AML cells dependent on glutamine and sensitizes them to ferroptosis by activating ATF4-regulated integrated stress responses. Overall, our data clarify how OPA1 up-regulation allows AML cells' metabolic flexibility and survival and nominates specific OPA1 inhibitors as efficacious tools to overcome venetoclax resistance in leukemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
- Department of Pediatrics at Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
- Rutgers Cancer Institute, New Brunswick, NJ 08901, USA.
- Department of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
- Department of Pediatrics Hematology/Oncology/Bone Marrow Transplant, University of Colorado, Anschutz Medical Campus, Aurora, CO 13123, USA.
- Veneto Institute of Molecular Medicine, Padua 35129, Italy.
ORCID-Profile: Sofia La Vecchia, Saurav Doshi, Petros Antonoglou, Tanima Kundu, Matthew T Witkowski, Anna Pellattiero, Federico Magrin, Kristina Ames, Amit Verma, Kira Gritsman, Xiaoyang Su, Andrea Mattarei, Iannis Aifantis, Luca Scorrano, Christina Glytsou
Förderung
- NCI NIH HHS
- NIEHS NIH HHS
- NIH HHS
- NIDDK NIH HHS
- NHLBI NIH HHS
Zitieren
APA
La Vecchia, S., Doshi, S., Antonoglou, P., Kundu, T., Al Santli, W., Avrampou, K., Witkowski, M. T., Pellattiero, A., Magrin, F., Ames, K., Verma, A., Gritsman, K., Su, X., Mattarei, A., Aifantis, I., Scorrano, L., & Glytsou, C. (2025). Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia. Science Advances, 11(42). https://doi.org/10.1126/sciadv.adx8662
Vancouver
La Vecchia S, Doshi S, Antonoglou P, Kundu T, Al Santli W, Avrampou K, et al. Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia. Science Advances. 2025;11(42). doi:10.1126/sciadv.adx8662
BibTeX
@article{LaVecchia2025,
author = {La Vecchia, Sofia and Doshi, Saurav and Antonoglou, Petros and Kundu, Tanima and Al Santli, Wafa and Avrampou, Kleopatra and Witkowski, Matthew T and Pellattiero, Anna and Magrin, Federico and Ames, Kristina and Verma, Amit and Gritsman, Kira and Su, Xiaoyang and Mattarei, Andrea and Aifantis, Iannis and Scorrano, Luca and Glytsou, Christina},
title = {Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {42},
doi = {10.1126/sciadv.adx8662}
}
EUVIMED